暴露前预防（PrEP）用于预防 HIV 感染的临时指南更新：为注射吸毒者提供 PrEP。

Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users.

出版信息

MMWR Morb Mortal Wkly Rep. 2013 Jun 14;62(23):463-5.

DOI:

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4604844/

Abstract

On June 12, 2013, the Thailand Ministry of Health and CDC published results from a randomized controlled trial of a daily oral dose of 300 mg of tenofovir disoproxil fumarate (TDF) that showed efficacy in reducing the acquisition of human immunodeficiency virus (HIV) infection among injecting drug users (IDUs) (1). Based on these findings, CDC recommends that preexposure prophylaxis (PrEP) be considered as one of several prevention options for persons at very high risk for HIV acquisition through the injection of illicit drugs.

摘要

2013 年 6 月 12 日，泰国卫生部和疾病预防控制中心发布了一项关于每日口服 300 毫克替诺福韦酯富马酸二异丙酯（TDF）的随机对照试验结果，该试验表明该药物可有效降低注射吸毒者（IDUs）感染人类免疫缺陷病毒（HIV）的风险（1）。基于这些发现，疾病预防控制中心建议将暴露前预防（PrEP）作为通过注射非法药物感染 HIV 的高危人群的几种预防选择之一。